Moneycontrol PRO
Upcoming Webinar:Innovate Your Future at India Inc. on the Move on August 26 and 27, 2021 at 10am, with Rockwell Automation
you are here: HomeNewsIndia

COVID-19 | Delta variant mutates, may be resistant to antibodies cocktail: Report

The Delta variant (B.1.617.2) of SARS-CoV-2 was first detected in India in October 2020, and has been classified by the World Health Organization (WHO) as a variant of concern.

June 14, 2021 / 09:47 AM IST
The Delta variant (B.1.617.2) of SARS-CoV-2 was first detected in India in October 2020, and has been classified by the World Health Organization (WHO) as a variant of concern.

The Delta variant (B.1.617.2) of SARS-CoV-2 was first detected in India in October 2020, and has been classified by the World Health Organization (WHO) as a variant of concern.

The Delta variant of the coronavirus has mutated into a version that could possibly be resistant to monoclonal antibodies cocktail used in COVID-19 treatment, The Times of India has reported.

The Delta variant (B.1.617.2) of SARS-CoV-2 was first detected in India in October 2020 and has been classified by the World Health Organization (WHO) as a variant of concern.

Public Health England (PHE), a UK government body, said India has reported six cases of Delta-AY.1 as of June 7. Delta-AY.1 has acquired the spike protein mutation K417N, the report said citing information from GISAID.

"As of 7 June 2021, 63 genomes of Delta with K417N have been identified on GISAID. from Canada (1) Germany (1), Russia (1), Nepal (2), Switzerland (4), India (6), Poland (9), Portugal (12), Japan (13), USA (14)," PHE said on June 11 in its updated document on coronavirus variants.

There are currently 36 cases of Delta-AY.1 in England, the document added.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Also read: In-Depth | Decoding the Delta variant of coronavirus and growing concerns around it

The K417N mutation is also one of the mutations found in the Beta variant (B.1.351) of SAR-CoV-2, which was first detected in South Africa.

The Times of India report pointed to tweets by Dr Vinod Scaria, clinician and computational biologist, Institute of Genomics and Integrative Biology (IGIB), New Delhi.

In a Twitter thread, Dr. Scaria gave some insight into the emerging lineages of Delta variant of the coronavirus.

"A number of genomes are now available for the lineage AY.1 / B.1.617.2.1 from across the world. The sequences are mostly from Europe, Asia and America. The travel histories are not readily available to make assumptions," he said.

"One important point to consider regarding K417N is evidence suggesting resistance to mAbs Casirivimab and Imdevimab. The mAb cocktail incidentally has received a EUA from @CDSCO_INDIA_INF in India. The variant freq for K417N is not much in India at this point in time," Dr Scaria tweeted.
Moneycontrol News
first published: Jun 14, 2021 09:47 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark